BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017;22:1451-1462. [PMID: 28642335 DOI: 10.1634/theoncologist.2017-0149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist 2019;24:1446-52. [PMID: 31189618 DOI: 10.1634/theoncologist.2018-0921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
3 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 18.5] [Reference Citation Analysis]
4 Wu T, Yang F, Chan WWL, Lam CLK, Wong CKH. Healthcare utilization and direct medical cost in the years during and after cancer diagnosis in patients with type 2 diabetes mellitus. J Diabetes Investig 2020;11:1661-72. [PMID: 32471010 DOI: 10.1111/jdi.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 2021. [PMID: 34378163 DOI: 10.1007/s40273-021-01071-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 2018;36:1005-13. [PMID: 29682693 DOI: 10.1007/s40273-018-0656-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Modlin IM, Kidd M, Oberg K, Falconi M, Filosso PL, Frilling A, Malczewska A, Salem R, Toumpanakis C, Laskaratos FM, Partelli S, Roffinella M, von Arx C, Kudla BK, Bodei L, Drozdov IA, Kitz A. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Ann Surg Oncol 2021. [PMID: 34008138 DOI: 10.1245/s10434-021-10021-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Cives M, Pellè E, Silvestris F. The management of refractory carcinoid syndrome: challenges and opportunities ahead. J Med Econ 2018;21:241-3. [PMID: 29039712 DOI: 10.1080/13696998.2017.1394312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
11 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
12 Tanaka H, Uema D, Rego JFM, Weschenfelder RF, D'Agustini N, Filho DRR, O'Connor JM, Luca R, Nuñez JER, de Barros E Silva MJ, Riechelmann RP. Health resource utilisation by patients with neuroendocrine tumours with or without carcinoid heart disease: a multinational study. Ecancermedicalscience 2020;14:1141. [PMID: 33343700 DOI: 10.3332/ecancer.2020.1141] [Reference Citation Analysis]
13 Dasari A, Joish VN, Perez-olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Review of Pharmacoeconomics & Outcomes Research 2020;20:507-11. [DOI: 10.1080/14737167.2019.1660646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]